The role of the Biology Core is to characterize the compounds synthesized by the Chemistry Core (Core B) using GEMS luciferase reporter assays, ELISA, and western blot analysis. The data generated by these assays is reported back to the Chemistry Core to help make decisions regarding the subsequent rounds of chemical synthesis. Analog synthesis and biological screening are performed iteratively, allowing for refinement of the lead molecules described in the Chemistry Core section. This effort is expected to allow for a variety of structures to identify compounds with improved efficacy, selectivity, and physicochemical and pharmacokinetic properties. In addition, the results generated by the Biology Core will be used to determine the compounds that will be characterized by the Pharmacology Core (Core C). Compounds that are active in the biological assays will be evaluated in pharmacological assays and then continue to the Efficacy Assessment Core (Core D) for ex vivo studies using muscles from mdx mice and eventually in vivo studies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54NS058572-03
Application #
7879232
Study Section
National Institute of Neurological Disorders and Stroke Initial Review Group (NSD)
Project Start
Project End
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
3
Fiscal Year
2009
Total Cost
$499,514
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Nelson, Michael D; Rader, Florian; Tang, Xiu et al. (2014) PDE5 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy. Neurology 82:2085-91